Here are 1-3 brief analogies to describe AquaBounty Technologies (AQB):

• Bayer Crop Science for aquaculture.
• A biotechnology company like a food-focused Genentech or Amgen.

• AquAdvantage Salmon: A bioengineered Atlantic salmon offered for human consumption.
• Conventional Atlantic Salmon: Standard Atlantic salmon sold for human consumption.
• Salmon Eggs: Eggs from salmon, typically sold for aquaculture.
• Salmon Fry: Young salmon, often sold for further growth in aquaculture operations.
• Salmon Byproducts: Materials derived from salmon processing.

Major Customers of AquaBounty Technologies (AQB)

AquaBounty Technologies (AQB) primarily operates on a business-to-business (B2B) model, selling its products to other companies within the commercial aquaculture and seafood supply chain. While the company does not publicly disclose the names of its specific major customers, its sales are directed towards the following categories of businesses:

• Seafood Distributors: These companies purchase AquAdvantage Salmon and conventional Atlantic salmon from AquaBounty and distribute them to a wide range of clients, including retail grocery chains, restaurants, and other foodservice providers.
• Wholesale Foodservice Providers: AquaBounty supplies salmon products to wholesalers who, in turn, sell to restaurants, hotels, institutional cafeterias, and other entities in the foodservice industry.
• Retail Grocery Chains: Some sales may be made directly to large retail grocery chains, or indirectly through seafood distributors, for sale to individual consumers.
• Other Aquaculture Farms: AquaBounty sells salmon eggs and fry to other commercial aquaculture operations that grow the fish to market size.

David A. Frank Chief Financial Officer, Treasurer and Interim Chief Executive Officer

Mr. Frank was appointed Interim Chief Executive Officer of AquaBounty Technologies on December 6, 2024, in addition to his role as Chief Financial Officer and Treasurer, which he assumed in October 2007. He possesses over 28 years of financial-management experience and 17 years of experience in the seafood and aquaculture industries. His background includes serving as President and General Manager of TekCel LLC, a subsidiary of Magellan Biosciences, where he was also CFO of Magellan Biosciences since its founding in 2004 and TekCel's CFO since 2003. Mr. Frank also held the CFO position at SmartEnergy during a period of rapid growth, increasing revenue from under $1 million to over $45 million between 2000 and 2002. He was corporate controller for Moldflow during its successful public offering and held earlier financial roles at PerSeptive Biosystems, Lotus Development Corporation, Apollo Computer, and Honeywell. He has extensive experience with early-stage public and private companies, including completing financing transactions for initial start-up, growth, and mergers & acquisitions.

Chris Bucich Vice President, Facilities Construction & Continuous Improvement

Mr. Bucich is responsible for leading the complex buildout of AquaBounty's Ohio Farm. He has experience in enhancing end-to-end operational and corporate infrastructure through process improvements, applying lean six sigma and continuous improvement principles.

1. Lack of Market and Consumer Acceptance: Despite regulatory approvals in the U.S. and Canada, AquaBounty's AquAdvantage Salmon encountered widespread consumer and retailer rejection. Major grocery retailers and food service companies committed to not selling the genetically engineered product, often due to public concerns and campaigning by environmental and Indigenous groups. This limited market access and demand proved to be a dominant impediment to commercial viability.
2. Significant Financial Losses and Liquidity Issues: AquaBounty has a history of substantial net losses, amounting to $369 million since its incorporation, and has faced persistent financial instability. The company has struggled to raise sufficient capital to sustain operations, leading to the sale of assets, including its Indiana farm and Canadian facilities, and the halting of construction on its Ohio farm project. Ultimately, insufficient liquidity forced the company to wind down all fish farming operations and cull its remaining fish stock.
3. Regulatory and Legal Challenges with Public Opposition: While AquAdvantage Salmon received initial regulatory approvals, these were often met with legal challenges. A U.S. federal judge ruled in 2020 that the FDA's approval violated environmental laws, requiring reassessment of potential environmental harms, such as the risk of genetically engineered salmon escaping and impacting wild populations. This ongoing regulatory scrutiny, combined with strong public and environmental advocacy against GE animals, created significant hurdles and contributed to the product's market difficulties.

The clear emerging threat for AquaBounty Technologies is the rapid advancement and potential commercialization of **cell-based (cultivated) seafood technologies**, particularly for salmon.

Companies in this space are developing methods to produce salmon meat directly from cells, bypassing traditional aquaculture entirely. If these technologies scale to become cost-competitive and palatable to consumers, they could fundamentally disrupt the aquaculture industry, including AquaBounty's niche of bioengineered salmon. This presents a new paradigm for seafood production that could render AquaBounty's enhanced farming methods less relevant, similar to how streaming services threatened DVD rental businesses.

AquaBounty Technologies, Inc. (AQB) focuses on the commercial aquaculture industry, primarily with products related to Atlantic salmon. Their main product, AquAdvantage Salmon, is a bioengineered Atlantic salmon designed for human consumption, and they also sell conventional Atlantic salmon, salmon eggs, fry, and byproducts.

The addressable markets for products related to Atlantic salmon, which AquaBounty Technologies' offerings are designed to serve, include:

• United States: The Atlantic salmon market in the United States was estimated to be approximately USD 993.85 million in 2025. This figure is derived from the total United States salmon market, which was valued at USD 1,529 million in 2025, with Atlantic salmon accounting for 65% of this market. The overall United States salmon market is projected to reach USD 2,030.97 million by 2034.
• Canada: The total farmed finfish market in Canada, which is largely dominated by Atlantic salmon, was valued at $1.1 billion in 2023. Canada's exports of Atlantic salmon are significant, with the United States being the largest export market.
• Global: The global Atlantic salmon market was valued at approximately USD 19.9 billion in 2023 and is projected to grow to about USD 26.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1% during this forecast period.

Here are 3 expected drivers of future revenue growth for AquaBounty Technologies (AQB) over the next 2-3 years:

1. Increased Production Volume of AquAdvantage Salmon from the Ohio Facility: The successful completion and ramp-up of operations at the Ohio farm project are anticipated to be a primary driver of revenue growth. This facility is projected to have a significant annual production capacity of genetically engineered AquAdvantage Salmon, which would substantially increase the company's output for commercial sale.

2. Expansion of Market Reach and Customer Base for AquAdvantage Salmon: As production capacity from facilities like the Ohio farm increases, AquaBounty is expected to expand its distribution networks and secure additional customers for its AquAdvantage Salmon within approved markets in the United States and Canada. This expansion aims to capture a larger share of the aquaculture market by leveraging the faster growth rate and efficiency of its product.

3. Sales of Conventional Atlantic Salmon Eggs to Other Aquaculture Operators: While the company is restructuring some of its farming operations, its expertise in fish breeding and genetics, as well as its historical sales of conventional Atlantic salmon eggs, could continue to be a revenue stream. AquaBounty has previously secured significant orders for conventional eggs, indicating a market for this product that could be sustained or developed through partnerships or licensing of its genetic lines.

Share Issuance

• AquaBounty Technologies announced a registered direct offering on February 12, 2026, for 1,269,509 shares of common stock and pre-funded warrants for 67,706 shares, anticipating approximately $1,150,000 in gross proceeds.
• The number of shares outstanding for AquaBounty Technologies increased from approximately 3 million at the end of 2021 to 4 million by September 30, 2025.
• Shareholders experienced substantial dilution in the past year, as noted in a March 13, 2026, report.

Inbound Investments

• AquaBounty Technologies received $4 million in funding on November 4, 2025, through a transaction involving 9 investors who were issued securities under Regulation D.
• The company has raised a total of $10 million in funding over nine rounds.
• A "Conventional Debt" funding round occurred on October 28, 2025.

Capital Expenditures

• In the 12 months leading up to March 6, 2026, AquaBounty Technologies' capital expenditures totaled -$256,277.
• The company invested $256K in capital expenditures in Q4 2024, representing a 62.0% decrease from the previous quarter.
• Capital allocation for expenditures has been directed towards the Ohio Farm Site, while the company announced plans to cease fish farming operations at its Bay Fortune hatchery in Canada in December 2024.